Impact Factor
3.45
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
2.71
829 total citations
h5-index
38
h5 depth signal
Cited share
66.4%
219 of 330
Total citations
829
Citation footprint
Metric signal
2.92
External metric anchor
Self-citation
4.0%
33 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United Kingdom
464
United States
302
China
265
Australia
239
Italy
114
Citing Fields of Research
Endocrinology & Metabolism
1,353
Adrenal Dysfunction
428
Human Reproduction
282
Diabetes
199
Endocrine Therapy
191
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
11,859
Articles tracked across the journal lifetime
Indexed publication set
330
219 cited publications
Last 12 months
168
14.0 publications/month
Open access share
39.9%
67 OA publications in the last year
Leading citing country
United Kingdom
464 citing publications
Leading citing field
Endocrinology & Metabolism
1,353 citing publications
Latest tracked publication
20 October 2026
10 recent records available
Coverage & Indexing History
v1n1,Jan. 1972-
v1n1,Jan. 1972-
Active Coverage
Research Focus & Classification
Indexed Subjects
Endocrinology & Metabolism
Broad Categories
Endocrinology
Endocrinology & Metabolism
Adrenal Dysfunction
Human Reproduction
Osteopathies
MeSH Descriptors
Endocrinology
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
02
DOI 10.1111/cen.70219
Open DOI
Endoscopic Ultrasound‐Guided Ethanol Ablation for Benign Insulinoma: A Single‐Centre Experience and Literature Review
Objectives: Insulinoma is a predominantly benign pancreatic neuroendocrine tumour that is traditionally managed surgically. However, surgical invasiveness and anaesthesia‐related risks limit its applicability in selected patients. Endosc...
03
DOI 10.1111/cen.70220
Open DOI
LGALS3 Drives Dopamine Agonist Resistance in Prolactinoma by Activating the MAPK/ERK Pathway: A Multi‐Omics Study
Background: Dopamine agonist resistance is observed in 10%–30% of patients with prolactinomas, resulting in therapeutic failure and tumour progression. The molecular mechanisms underlying this resistance are not yet fully understood, hig...
04
DOI 10.1111/cen.70221
Open DOI
Survival in Patients With Pituitary Carcinoma
Objective: Pituitary carcinoma (PC) is defined by the presence of metastasis from a pituitary tumour. PC is rare, therefore information regarding survival and factors influencing survival are limited. We sought to assess overall survival...
05
06
DOI 10.1111/cen.70217
Open DOI
Increased Risk of Thyrotoxicosis After COVID‐19 in Adolescents and Young Adults During the Omicron‐Predominant Period: A Nationwide Matched Study
Objective: Thyroid dysfunction has been increasingly reported after the coronavirus disease 2019 (COVID‐19) pandemic. To date, no population‐based study has examined this association using more than 10 million matched pairs. We compared ...
07
DOI 10.1111/cen.70218
Open DOI
Cortisol Cutoffs for Adrenal Insufficiency Using Elecsys II: A Systematic Review
Objective: Adrenal insufficiency (AI) is associated with increased risk of morbidity and mortality if improperly managed. Adrenocorticotrophin (ACTH) stimulation testing is the most widely used AI diagnostic test. Historically, a serum c...
08
DOI 10.1111/cen.70222
Open DOI
Adrenal Infections: An Underrecognized Cause of Primary Adrenal Insufficiency
Introduction: Adrenal infections are an underrecognized but clinically significant cause of primary adrenal insufficiency (PAI). Objectives: This review proposes a diagnostic algorithm for the evaluation of suspected cases. Results: The ...
09
DOI 10.1111/cen.70211
Open DOI
Multidisciplinary Care Model for Differences in Sex Development: An Implementation Research Study
Objective: To initiate a multidisciplinary care model for patients with differences in sex development (MD‐DSD), assess its implementation, and evaluate changes in perceived quality of care following implementation among parents and heal...
10
DOI 10.1111/cen.70209
Open DOI
Cardiometabolic Protein Profile Changes During Gender‐Affirming Hormone Therapy: A Prospective Clinical Study
Objective: Cardiovascular disease (CVD) risk is elevated in transgender individuals during gender‐affirming hormone therapy (GAHT) with expected different mechanisms between T‐ and E2‐based GAHT. We investigated prospective changes in ca...
Bibliographical & Catalog Notes
Supplements accompany some vols.
Also issued online.
Vol. 12, no. 1 (1980)19920818 Notice not published Printed on acid-free paper